Gilteritinib
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Adult Indications and Dosage
Plasma Concentration
- After 15 days, the plasma concentration becomes steady
- Maximum Concentration: 374 ng/mL
- AUC: 6943 ng.h/mL
- The Data is different in people who are fasting
- The Maximum Concentration decreased by 26%
- AUC decreased by 10%
Excretion
- About 64.5% of the administered dose is excreted in the feces
- About 16.4% of the administered dose goes through the urine
Distribution
- Central Volume of Distribution is approximately 1092 L
- Peripheral Volume of Distribution is approximately 1100 L
Pediatric Indications and Dosage
Contradictions
Warnings
Adverse Reactions
Differentiation Syndrome
- May result in some "life-threatening symptoms" known as differentiation syndrome
- Contact doctor immediately if any of these symptoms occur:
- Fever, cough rash, rapid weight gain, vertigo, urination problems, joint swelling, difficulty breathing, chest pain, or joint pain
Side Effects
- If persists, call a doctor:
- joint/muscle pain, severe tiredness, acute vomiting and nausea, diarrhea, mouth sores, loss in taste/ appetite, headache or insomnia
- More Serious
- Seizures, difference in heartbeat, persisting pain in the abdomen region that could spread to the back
Drug Interactions
Use in Specific Populations
Administration and Monitoring
IV Compatibility
Overdosage
Pharmacology
Clinical Studies
How is it Supplied
Patient Counseling Information
Precautions with Alcohol
Brand Names
Names of Drugs that Look Alike
Drug Shortage Status
Price
Contraindicated Medications
{{MedCondContrAbs |MedCond = NameOfTheContraindication|Drug1|Drug2|Drug3}}